![Phio Pharmaceuticals Corporation](/common/images/company/N_PHIO.png)
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipelin... Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. Show more
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLβ’ siRNA gene silencing technology...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.5597 | -14.8868260765 | 3.7597 | 4.09 | 3.1245 | 98110 | 3.72629443 | CS |
4 | 2.62 | 451.724137931 | 0.58 | 6.18 | 0.57 | 82910 | 3.77513969 | CS |
12 | 2.372 | 286.473429952 | 0.828 | 6.18 | 0.57 | 70736 | 1.92329254 | CS |
26 | 2.6 | 433.333333333 | 0.6 | 6.18 | 0.5459 | 261331 | 0.97156202 | CS |
52 | 0.49 | 18.0811808118 | 2.71 | 6.18 | 0.5 | 523467 | 1.81965281 | CS |
156 | -18.4 | -85.1851851852 | 21.6 | 29.04 | 0.5 | 652658 | 14.05329073 | CS |
260 | -1.48 | -31.6239316239 | 4.68 | 130.2 | 0.5 | 721768 | 19.11535428 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.